Dravet Syndrome
Conditions
Brief summary
The present study aims to collect data regarding the history of the disease, previous and current treatments, and the clinical status of Dravet patients during the 3 months prior to stiripentol initiation, the first 3 months on stiripentol and the last 3 months on stiripentol (irrespective of stiripentol discontinuation).
Interventions
OTHERRetrospective study
Retrospective study
Sponsors
Biocodex
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Patients diagnosed with Dravet syndrome * Treated with stiripentol for a minimum of 3 months in routine practice
Exclusion criteria
* NA
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| management of the Dravet syndrome | through study completion, an average of 1 year | Patient Information History of the Disease Clinical status of the patient during the 3 months preceding stiripentol treatment initiation Clinical status of the patient at stiripentol initiation Clinical status of the patient during the first 3 months of stiripentol treatment Clinical status of the patient during the last 3 months of stiripentol treatment Evolution on stiripentol |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Better detection of the Dravet syndrome | through study completion, an average of 1 year | Patient Information History of the Disease Clinical status of the patient during the 3 months preceding stiripentol treatment initiation Clinical status of the patient at stiripentol initiation Clinical status of the patient during the first 3 months of stiripentol treatment Clinical status of the patient during the last 3 months of stiripentol treatment Evolution on stiripentol |
Countries
United States
Outcome results
None listed